NCT04461171 Enhanced Recovery After Surgery in Extremity Sarcoma
| NCT ID | NCT04461171 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Joshua Lawrenz |
| Condition | Sarcoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2020-12-14 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2020-12-14 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.
Eligibility Criteria
Inclusion Criteria: * Any patient at Vanderbilt University Medical Center treated with surgical excision of a suspected extremity sarcoma * Adult patients \>17 years of age * Patients of all preoperative opioid status (naïve or dependent) Exclusion Criteria: * Patients treated non-operatively * Non-English speaking patients
Contact & Investigator
Joshua Lawrenz, MD
PRINCIPAL INVESTIGATOR
Vanderbilt Medical Center
Frequently Asked Questions
Who can join the NCT04461171 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04461171 currently recruiting?
Yes, NCT04461171 is actively recruiting participants. Contact the research team at cip@vumc.org for enrollment information.
Where is the NCT04461171 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT04461171 clinical trial?
NCT04461171 is sponsored by Joshua Lawrenz. The principal investigator is Joshua Lawrenz, MD at Vanderbilt Medical Center. The trial plans to enroll 120 participants.